[Calculation of direct standard costs in the evaluation of new technologies: application to the treatment of acute myeloblastic leukemias].
Financial incidence of new technology can be approached through the utilization of "direct standard cost". This method allows actualization of prices and permits the integration of new procedures. It is applied to acute non lymphoblastic leukemia.